| Study characteristics |
| Methods |
Prospective cohort |
| Participants |
N = 334 in US children aged 10 months to 6 years old |
| Interventions |
MMR vaccine (Merck Sharp & Dohme containing measles strain Moraten 1000 TCID50, mumps strain Jeryl Lynn 5000 TCID50, rubella strains HPV ‐ 77 1000 TCID50) 1 dose subcutaneous
versus
No treatment |
| Outcomes |
Temperature (> 38 °C in US, no range given in Costa Rica) Conjunctivitis, upper respiratory tract illness, lymphadenopathy, gastroenteritis, fretfulness, malaise and anorexia, measles‐like rash, arthralgia (only in Costa Rica). Follow‐up 28 days |
| Funding Source |
Government |
| Notes |
Two studies (one in US, one in Costa Rica) were reported in the one study. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| PCS/RCS ‐ exposed cohort selection |
High risk |
There was insufficient information. |
| PCS/RCS ‐ non‐exposed cohort selection |
High risk |
There was insufficient information. |
| PCS/RCS ‐ comparability |
High risk |
No adjustment by confounders |
| PCS/RCS ‐ assessment of outcome |
High risk |
Self‐reported |
| Summary Risk of Bias assessment |
High risk |
We had concerns regarding multiple domains such that our confidence in the result is substantially lowered. |
